CLAIMS

1. Use of a TACI-Fc fusion protein in the manufacture of a medicament for treating primary Sjogren's syndrome (pSS), wherein the TACI-Fc fusion protein comprises:

(i) a TACI extracellular region or a fragment thereof binding to BLyS and/or APRIL; and

(ii) a fragment of human immunoglobulin constant region.

2. The use according to claim 1, wherein the TACI extracellular region or the fragment thereof binding to BLyS and/or APRIL comprises an amino acid sequence set forth in SEQ ID NO: 1.

3. The use according to claim 2, wherein the human immunoglobulin is IgG1, or the fragment of human immunoglobulin constant region comprises an amino acid sequence set forth in SEQ ID NO: 2 or an amino acid sequence having at least 90%, at least 91%, at least 92%, at least 93%, at least 95%, or at least 96% identity to the amino acid sequence set forth in SEQ ID NO: 2.

4. The use according to claim 3, wherein the fragment of human immunoglobulin constant region comprises one or more modifications of amino acid at positions 3, 8, 14, 15, 17, 110, 111, or 173 of SEQ ID NO: 2.

5. The use according to claim 4, wherein the modification is substitution, deletion, or insertion of amino acid.

6. The use according to claim 5, wherein the substitution is selected from the group consisting of P3T, L8P, L14A, L15E, G17A, A110S, P111S, and A173T.

7. The use according to claim 6, wherein the fragment of human immunoglobulin constant region comprises an amino acid sequence set forth in SEQ ID NO: 3.

8. The use according to claim 1, wherein the TACI-Fc fusion protein has an amino acid sequence set forth in SEQ ID NO: 4.

9. The use according to claim 8, wherein the TACI-Fc fusion protein is telitacicept.

10. The use according to claim 8 or 9, wherein the TACI-Fc fusion protein is to be administered at a dose of 0.1 to 10 mg/kg.

11. The use according to claim 8 or 9, wherein the TACI-Fc fusion protein is to be

administered at a dose of 160 to 240 mg, preferably 160 mg or 240 mg.

12. The use according to claim 11, wherein the TACI-Fc fusion protein is to be administered subcutaneously, intramuscularly, or intravenously, or at the thigh, abdomen, or upper arm.

13. The use according to claim 11, wherein the TACI-Fc fusion protein is to be administered 2-4 times per month.

14. The use according to claim 13, wherein the TACI-Fc fusion protein is to be administered at a frequency of once a week.

15. The use according to claim 14, wherein the TACI-Fc fusion protein is to be administered for 2-50 weeks.

16. The use according to claim 14, wherein the TACI-Fc fusion protein is to be administered for 24 weeks.